Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment Volume 32, Number 19, July. 1, 2014, from J Clin Oncol Chen.

Slides:

Advertisements

Similar presentations

What Do We Do? Cancer Genetics Service for Wales.

Advertisements

“These data can inform policy discussion” Am J Hum Genet, October 3, 2013, 93:

Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.

Gene 210 Cancer Genomics April 29, Key events in investigating the cancer genome M R Stratton Science 2011;331:

Hereditary Factors in Breast Cancer

The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.

Genetics and Ovarian Cancer Jeanne M. Schilder, M.D. Associate Professor, Gynecologic Oncology Indiana University Medical Center September 19, 2012.

Breast Cancer Risk and Risk Assessment Models

Estimating the penetrances of breast and ovarian cancer in the carriers of BRCA1/2 mutations Silvano Presciuttini University of Pisa, Italy.

SURVIVORS TEACHING STUDENTS: SAVING WOMEN’S LIVES®

Type Of Cancer:Location: CarcinomaEpithelial Cells SarcomaConnective Tissue LeukemiaCirculatory / Lymphatic.

Gene 210 Cancer Genomics May 5, Key events in investigating the cancer genome M R Stratton Science 2011;331:

BRCA1 and BRCA2 Mutations and Breast Cancer: An Integrated Approach Using Four Epidemiologic Parameters Monica McClain, PhD. Assistant Director, Biometry.

BRCA Mutations and Breast Cancer Ruth Phillips and Patty Ashby.

Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.

FORCE XRAY PROGRAM Evaluating Reports on Breast Cancer in the Media.

Genetics & Colorectal Cancer

© Dr Whitcomb Familial Pancreatic Cancer Families (and other high-risk people) David C Whitcomb MD PhD Giant Eagle Foundation Professor of Cancer Genetics.

Genetics and Ovarian Cancer June 16, 2015 Ovarian Cancer Alliance of Oregon and SW Washington Becky Clark, MS, CGC Genetic Counselor.

Panagiotis Konstantinopoulos MD, PhD Assistant Professor of Medicine

Clinical Utility of BRCA Testing Mark Robson, MD September 7,

New Era of Genetic Testing in Colon Cancer

Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.

Summer Dewdney, MD Rush University Medical Center.

Breast Ovarian Hereditary Breast & Ovarian Cancer Knowing one’s family medical history can be life-saving.

Chapter 13: Chromosome 13 BCCIP mRNA transcription translation Amino acid sequence Name of Protein DNA Sequence Name of Gene Chromosome What does this.

Genetics: For this Generation and the Next

Uterine Cancer Endometrial (or uterine) cancer will account for 50,000 new cases and 8200 deaths in the United States in Two genetic disorders are.

Rachel Liao, PhD Coordinator of the Clinical Working Group and the BRCA Challenge demonstration project for the Global Alliance for Genomics and Health.

Genetic predisposition to

Hereditary Breast and Ovarian Cancer Syndrome

1 LYNCH SYNDROME EPCAM FAMILY WITH PREDOMINANT COLORECTAL CANCER HENRY T. LYNCH, MD; STEPHEN N. THIBODEAU, PHD; CARRIE SNYDER, MSN, RN, APNG; JENNIFER.

Pancreatic Cancer In 2012 there were 43,920 cases of pancreatic cancer. 10% of these cases have a family clustering of pancreatic cancers and associated.

BRCA testing in women with ovarian cancer Dr Carole Brewer Peninsula Clinical Genetics Service 15 January 2016.

Breast Cancer Ten percent of breast cancer is hereditary. Or 23,000 women a year with a genetic basis for their cancer. The most common mutations in this.

Towards Global Eminence K Y U N G H E E U N I V E R S I T Y Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic.

What Percentage of Cancer is Considered to be Hereditary?

Hereditary Breast and Ovarian Cancer Syndrome Developed by Ms. Shawna Morrison, Dr. June Carroll, and Dr. Judith Allanson Last updated May 2016.

Cancer Genetic Risk Assessment James Ford, MD and Nicki Chun, MS, LCGC Cancer Genetics Clinic Stanford Cancer Center November 5, 2015.

Date of download: 7/7/2016 From: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review.

Update on genetic testing for hereditary breast cancer syndromes Kristin DePrince Mattie, M.S. Licensed / Certified Genetic Counselor William G. Rohrer.

An Introduction to Cancer Genetics for Healthcare Interpreters Cynthia Roat, MPH; Galen Joseph, PhD Claudia Guerra MSW; Janice Cheng, PhD Robin Lee, LCGC;

Breast Cancer Risk Assessment & Prevention Strategies Generosa Grana, MD Professor, Cooper Medical School of Rowan University Director, MD Anderson Cancer.

Hereditary Cancer Predisposition: Updates in Genetic Testing

Pathways involved in hereditary breast cancer

Kristen Zarfos, MD Linda Steinmark, MS, LCGC

Kyle Salsbery Genetic Counselor

Susan Domchek, MD University of Pennsylvania

Demystifying Cancer Genetics

Hereditary Gastrointestinal Cancers

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Family Tree Presentation

GYN CANCER RISK AND GENETICS

New Approaches to Cancer Susceptibility Testing

Who in the room would offer BRCA1/2 testing to this patient Who in the room would offer BRCA1/2 testing to this patient? How might the medical management.

Genetics and Breast Cancer Adelphi 2018 Educational Forum Sharona Cohen, MS, CGC Certified Genetic Counselor Northwell Health.

Lorraine Hartles West Midlands Regional Genetics Laboratory

Counseling Patients About Germline BRCA Mutations

Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families Paul D.P. Pharoah,

DiagMMR™ assay validation sample collection

Specific Tumor Suppressor Genes

Familial Colorectal Cancer, Beyond Lynch Syndrome

Biology of hereditary breast and ovarian cancer (HBOC)

HBOC Genetic counseling: major concerns and communication skills

by Jennifer Couzin-Frankel

Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines

Diagnosis of breast cancer in women age 40 and younger: Delays in diagnosis result from underuse of genetic testing and breast imaging 95% of patients.

Volume 149, Issue 3, Pages e20 (September 2015)

Overall Survival and Progression-free Survival

Breast cancer BRCA testing protocol

Presentation transcript:

Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment Volume 32, Number 19, July. 1, 2014, from J Clin Oncol Chen Xinyi October 29,2015

BACKGROUND The BRCAs account for only about 25% of breast cancers with a hereditary component; Now unmasked dozens of other genes associated with breast cancer; Whether and how?

INTRODUCTION Sam Kean Science

QUESTION How many and which genes to sequence? Whether results are sufficiently understood to guide intervention? How best to counsel patients about variants of low or moderate penetrance?

GENE SELECTED Reported breast cancer association Associated with other cancer syndromes DNA repair pathways Rendering a breast cancer–risk association plausible

Participant Accrual 198 were randomly selected From 654 research samples for study participation; 174 breast cancer ； 57 carried a BRCA1/2 mutation ； Participants were representative

RESULT Pathogenic variants in BRCA1/2:57 Pathogenic variants in other genes:16 （ 11.4%; 95% CI, 7.0% to 17.7%) VUS Variants of Uncertain Significance:428

RESULT

ATM (2 women), BLM (1 woman), CDH1 (1 woman), CDKN2A (1 woman), MLH1(1 woman), MUTYH(1 women), NBN(2 women), PRSS1(1 woman), SLX4 (2 women).

VUS Variants of Uncertain Significance A total of 428 VUS were identified in 39 genes among 175 participants. Per participant, the average number of VUS across all genes was 2.1

RESULT Studies of multigene panel for hereditary cancers ReferenceNSubjectsPanel genes 1 Cancer 121, (2015)2158BC referred for BRCA gene testing25 2 Genet Med 16, (2014)2079hereditary cancer J Clin Oncol 33, (2015)1824TNBC17 4 J Mol Diagn 17, (2015)1105HBOC risk assessment under NCCN guideline29 5 JAMA Oncol (2015)1046non-BRCA HBOC 29 、 25 6 Eur J Hum Genet 22, (2014)93559 BRCA carriers+874 high-risk31 7 Gynecol Oncol 137, (2015)911BC/OC21 8 J Clin Oncol 33, 2015 (suppl; abstr 1511)810non-BRCA BC with high-risk features20 9 Proc Natl Acad Sci U S A 108, (2011)360primary ovarian, peritoneal, or fallopian tube carcinoma21 10 Ann Surg Oncol 22, (2015) underwent limited BRCA1/2 testing and 337 patients underwent panel testing Genet Med 17, (2015)278non-BRCA BC with early-onset22 12 J Clin Oncol 32, (2014) BC+57 BRCA carriers42 13 FEBS J 282, (2015)104non-BRCA BC312 1 Gastroenterology 149, e620 (2015)1260clinical genetic testing for Lynch syndrome25 2 Gastroenterology 148, (2015)708pancreatic cancers13 3 J Clin Oncol 33, (2015)626early-onset familial CRC5